Eleva’s drug candidate to be examined for use in Covid-19 treatment

Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken Read more about Eleva’s drug candidate to be examined for use in Covid-19 treatment[…]